NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. NVT
8. SPY
9. AAPL
10. LITE

Go back to NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit

NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains

April 27, 2016 7:00 AM EDT

FT. MYERS, Fla., April 27, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2016.

First Quarter 2016 Highlights:

159% increase in consolidated revenue to a record $59.7 million 442% increase in consolidated Adjusted EBITDA(1) to record $8.2 million 175% increase in consolidated clinical genetic testing volume(2) Adjusted Diluted EPS(1) of $0.03 per share and Diluted EPS of ($0.07) per share

Consolidated Revenue for the fourth quarter was $59.7... More